Skip to main content
Journal ArticleOPEN ACCESS

Safety, clinical activity and biomarkers of atezolizumab (atezo) in advanced ovarian cancer (OC)

  • Infante J
  • Braiteh F
  • Emens L
  • et al.
Annals of Oncology (2016) 27 vi300
DOI: 10.1093/annonc/mdw374.18
N/ACitations
Citations of this article
25Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Methods: Pts received atezo IV q3w (0.3-15 mg/kg) in a Ph Ia dose-escalation/expansion study (NCT01375842) and were treated until loss of clinical benefit. Confirmed ORR and PFS were assessed by RECIST v1.1. PD-L1 status on immune cells (IC) was centrally evaluated (VENTANA SP142 IHC assay) and scored as IC0, 1, 2, 3. After dose-escalation, only IC2 or 3 pts were enrolled. Molecular subtyping was performed using nanostring.

Cite

CITATION STYLE

APA

Infante, J. R., Braiteh, F., Emens, L. A., Balmanoukian, A. S., Oaknin, A., Wang, Y., … Gordon, M. (2016). Safety, clinical activity and biomarkers of atezolizumab (atezo) in advanced ovarian cancer (OC). Annals of Oncology, 27, vi300. https://doi.org/10.1093/annonc/mdw374.18

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free